Progenza
Knee Osteoarthritis
Phase 1/2aActive
Key Facts
About Cambium Bio
Australian‑based regenerative biotech advancing platelet‑lysate and MSC‑based therapies for eye, joint and wound indications.
View full company profileTherapeutic Areas
Other Knee Osteoarthritis Drugs
| Drug | Company | Phase |
|---|---|---|
| MAG200 | Magellan | Phase 3 |
| MUTI™ Knee Replacement | Meril | Commercial |
| DUROLANE | Bioventus | Commercial |
| XSTEM | Xintela | Phase I/IIa |
| Stempeucel® | Stempeutics Research | Commercial |
| Lipogems System for Knee Osteoarthritis | Lipogems International | Phase 3 |
| Signature Cord Prime™ | Arugula Sciences | Phase 1 |
| Knee Osteoarthritis Study | Arizona Research Center | Not Specified |
| 4P004 | 4Moving Biotech | Phase 2a |
| Lorecivivint (inferred) | Biosplice Therapeutics | Phase 3 |
| Regenerative Cell Therapy for Osteoarthritis | InGeneron | Phase 3 |
| ArthroCart | Arthro Biotech | Preclinical |